Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.

Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.

J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.

PMID:
30099369
2.

Precision therapeutic targeting of human cancer cell motility.

Xu L, Gordon R, Farmer R, Pattanayak A, Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, Chavez J, Bruce J, Mazar A, Nibbs A, Anderson W, Li L, Jovanovic B, Pruell S, Valsecchi M, Francia G, Betori R, Scheidt K, Bergan R.

Nat Commun. 2018 Jun 22;9(1):2454. doi: 10.1038/s41467-018-04465-5.

3.

The Role of Cruciferous Vegetables and Isothiocyanates for Lung Cancer Prevention: Current Status, Challenges, and Future Research Directions.

Zhang Z, Bergan R, Shannon J, Slatore CG, Bobe G, Takata Y.

Mol Nutr Food Res. 2018 Apr 16:e1700936. doi: 10.1002/mnfr.201700936. [Epub ahead of print] Review.

PMID:
29663679
4.

Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.

Wali RK, Bianchi L, Kupfer S, De La Cruz M, Jovanovic B, Weber C, Goldberg MJ, Rodriguez LM, Bergan R, Rubin D, Tull MB, Richmond E, Parker B, Khan S, Roy HK.

PLoS One. 2018 Apr 4;13(4):e0193544. doi: 10.1371/journal.pone.0193544. eCollection 2018.

5.

Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men.

Marshall JR, Burk RF, Payne Ondracek R, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R.

Oncotarget. 2017 Apr 18;8(16):26312-26322. doi: 10.18632/oncotarget.15460.

6.

A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Deibler KK, Mishra RK, Clutter MR, Antanasijevic A, Bergan R, Caffrey M, Scheidt KA.

ACS Chem Biol. 2017 May 19;12(5):1245-1256. doi: 10.1021/acschembio.6b01060. Epub 2017 Mar 20.

7.

A Way Forward for Cancer Chemoprevention: Think Local.

Al Rabadi L, Bergan R.

Cancer Prev Res (Phila). 2017 Jan;10(1):14-35. doi: 10.1158/1940-6207.CAPR-16-0194. Epub 2016 Oct 25. Review.

8.

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM.

Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547.

9.

Primary Aortoduodenal Fistula-A Case Report and a Review of the Literature.

Varghese M, Jorgensen GT, Aune C, Bergan R, Norderval S, Moland J.

Ann Vasc Surg. 2016 Jul;34:271.e1-4. doi: 10.1016/j.avsg.2015.12.013. Epub 2016 May 10. Review.

PMID:
27174358
10.

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.

Roy HK, Turzhitsky V, Wali R, Radosevich AJ, Jovanovic B, Della'Zanna G, Umar A, Rubin DT, Goldberg MJ, Bianchi L, De La Cruz M, Bogojevic A, Helenowski IB, Rodriguez L, Chatterton R, Skripkauskas S, Page K, Weber CR, Huang X, Richmond E, Bergan RC, Backman V.

Gut. 2017 Feb;66(2):285-292. doi: 10.1136/gutjnl-2015-309996. Epub 2015 Oct 26.

11.

Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort.

Hou L, Joyce BT, Gao T, Liu L, Zheng Y, Penedo FJ, Liu S, Zhang W, Bergan R, Dai Q, Vokonas P, Hoxha M, Schwartz J, Baccarelli A.

EBioMedicine. 2015 Apr 13;2(6):591-6. doi: 10.1016/j.ebiom.2015.04.008. eCollection 2015 Jun.

12.

The Coherent X-ray Imaging instrument at the Linac Coherent Light Source.

Liang M, Williams GJ, Messerschmidt M, Seibert MM, Montanez PA, Hayes M, Milathianaki D, Aquila A, Hunter MS, Koglin JE, Schafer DW, Guillet S, Busse A, Bergan R, Olson W, Fox K, Stewart N, Curtis R, Miahnahri AA, Boutet S.

J Synchrotron Radiat. 2015 May;22(3):514-9. doi: 10.1107/S160057751500449X. Epub 2015 Apr 15.

13.

Genistein suppresses FLT4 and inhibits human colorectal cancer metastasis.

Xiao X, Liu Z, Wang R, Wang J, Zhang S, Cai X, Wu K, Bergan RC, Xu L, Fan D.

Oncotarget. 2015 Feb 20;6(5):3225-39.

14.

Diminished expression of h2-calponin in prostate cancer cells promotes cell proliferation, migration and the dependence of cell adhesion on substrate stiffness.

Moazzem Hossain M, Wang X, Bergan RC, Jin JP.

FEBS Open Bio. 2014 Jun 24;4:627-36. doi: 10.1016/j.fob.2014.06.003. eCollection 2014.

15.

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA.

Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.

16.

Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.

Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC.

PLoS One. 2014 Jul 14;9(7):e102289. doi: 10.1371/journal.pone.0102289. eCollection 2014.

17.

Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.

Pavese JM, Bergan RC.

Cancer Lett. 2014 Oct 1;352(2):179-86. doi: 10.1016/j.canlet.2014.06.012. Epub 2014 Jul 10.

18.

Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.

Pavese JM, Krishna SN, Bergan RC.

Am J Clin Nutr. 2014 Jul;100 Suppl 1:431S-6S. doi: 10.3945/ajcn.113.071290. Epub 2014 May 28. Review.

19.

Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression.

Voll EA, Ogden IM, Pavese JM, Huang X, Xu L, Jovanovic BD, Bergan RC.

Oncotarget. 2014 May 15;5(9):2648-63.

20.

Circulating giant macrophages as a potential biomarker of solid tumors.

Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9. doi: 10.1073/pnas.1320198111. Epub 2014 Feb 18.

21.

Improving diversity in cancer research trials: the story of the Cancer Disparities Research Network.

Simon MA, de la Riva EE, Bergan R, Norbeck C, McKoy JM, Kulesza P, Dong X, Schink J, Fleisher L.

J Cancer Educ. 2014 Jun;29(2):366-74. doi: 10.1007/s13187-014-0617-y.

22.

Therapeutic modulation of prostate cancer metastasis.

Krishna SN, Bergan RC.

Future Med Chem. 2014 Feb;6(2):223-39. doi: 10.4155/fmc.13.201. Review.

PMID:
24467245
23.

A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.

Krishna SN, Luan CH, Mishra RK, Xu L, Scheidt KA, Anderson WF, Bergan RC.

PLoS One. 2013 Dec 5;8(12):e81504. doi: 10.1371/journal.pone.0081504. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/5edeb1de-b76c-4fd9-a3f6-0f1cf45e3905.

24.

An orthotopic murine model of human prostate cancer metastasis.

Pavese J, Ogden IM, Bergan RC.

J Vis Exp. 2013 Sep 18;(79):e50873. doi: 10.3791/50873.

25.

Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors.

Breen MJ, Moran DM, Liu W, Huang X, Vary CP, Bergan RC.

PLoS One. 2013 Aug 13;8(8):e72407. doi: 10.1371/journal.pone.0072407. eCollection 2013.

26.

A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia.

Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EEW, Blair E, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi V, Bergan RC, Szabo E.

Oral Oncol. 2013 Sep;49(9):970-976. doi: 10.1016/j.oraloncology.2013.05.011. Epub 2013 Jul 8.

27.

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.

Jin HJ, Zhao JC, Ogden I, Bergan RC, Yu J.

Cancer Res. 2013 Jun 15;73(12):3725-36. doi: 10.1158/0008-5472.CAN-12-3468. Epub 2013 Mar 28.

28.

Crystal structure of a type II dehydroquinate dehydratase-like protein from Bifidobacterium longum.

Light SH, Krishna SN, Bergan RC, Lavie A, Anderson WF.

J Struct Funct Genomics. 2013 Mar;14(1):25-30. doi: 10.1007/s10969-013-9149-7. Epub 2013 Mar 29.

29.

Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.

Dew A, Khan S, Babinski C, Michel N, Heffernan M, Stephan S, Jordan N, Jovanovic B, Carney P, Bergan R.

Clin Trials. 2013 Apr;10(2):292-9. doi: 10.1177/1740774512471452. Epub 2013 Jan 15.

PMID:
23321266
30.

Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.

Khan SA, Chatterton RT, Michel N, Bryk M, Lee O, Ivancic D, Heinz R, Zalles CM, Helenowski IB, Jovanovic BD, Franke AA, Bosland MC, Wang J, Hansen NM, Bethke KP, Dew A, Coomes M, Bergan RC.

Cancer Prev Res (Phila). 2012 Feb;5(2):309-19. doi: 10.1158/1940-6207.CAPR-11-0251.

31.

Methyl selenocysteine: single-dose pharmacokinetics in men.

Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R.

Cancer Prev Res (Phila). 2011 Nov;4(11):1938-44. doi: 10.1158/1940-6207.CAPR-10-0259. Epub 2011 Aug 16.

32.

The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research.

Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC.

Cancer Prev Res (Phila). 2011 Apr;4(4):616-21. doi: 10.1158/1940-6207.CAPR-11-0018.

33.

Endoglin regulates cancer-stromal cell interactions in prostate tumors.

Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA, Bergan RC, Brooks PC, Vary CP.

Cancer Res. 2011 May 15;71(10):3482-93. doi: 10.1158/0008-5472.CAN-10-2665. Epub 2011 Mar 28. Erratum in: Cancer Res. 2012 Feb 15;72(4):1037.

34.

Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression.

Farmer RL, Biddle MM, Nibbs AE, Huang X, Bergan RC, Scheidt KA.

ACS Med Chem Lett. 2010 Nov 11;1(8):400-405.

35.

Endoglin suppresses human prostate cancer metastasis.

Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, Romero D, Vary CP, Bergan RC.

Clin Exp Metastasis. 2011 Jan;28(1):39-53. doi: 10.1007/s10585-010-9356-6. Epub 2010 Oct 28.

36.

Inhibition of cancer cell invasion and metastasis by genistein.

Pavese JM, Farmer RL, Bergan RC.

Cancer Metastasis Rev. 2010 Sep;29(3):465-82. doi: 10.1007/s10555-010-9238-z. Review.

37.

Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, Vary CP.

Carcinogenesis. 2010 Mar;31(3):359-66. doi: 10.1093/carcin/bgp217. Epub 2009 Sep 7.

38.

MEK4 function, genistein treatment, and invasion of human prostate cancer cells.

Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, Jovanovic B, Wellman K, Killmer J, Huang X, Scheidt KA, Montgomery RB, Bergan RC.

J Natl Cancer Inst. 2009 Aug 19;101(16):1141-55. doi: 10.1093/jnci/djp227. Epub 2009 Jul 28.

39.

Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability.

Thurn KT, Paunesku T, Wu A, Brown EM, Lai B, Vogt S, Maser J, Aslam M, Dravid V, Bergan R, Woloschak GE.

Small. 2009 Jun;5(11):1318-25. doi: 10.1002/smll.200801458.

40.

Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images.

Paunesku T, Ke T, Dharmakumar R, Mascheri N, Wu A, Lai B, Vogt S, Maser J, Thurn K, Szolc-Kowalska B, Larson A, Bergan RC, Omary R, Li D, Lu ZR, Woloschak GE.

Nanomedicine. 2008 Sep;4(3):201-7. doi: 10.1016/j.nano.2008.04.004. Epub 2008 Jun 24.

41.

Dietary genistein inhibits metastasis of human prostate cancer in mice.

Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I, Pelling JC, Bergan RC.

Cancer Res. 2008 Mar 15;68(6):2024-32. doi: 10.1158/0008-5472.CAN-07-1246.

42.

Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.

Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC.

Mol Carcinog. 2008 Sep;47(9):686-700. doi: 10.1002/mc.20421.

PMID:
18240292
43.

The methodology used to measure differential gene expression affects the outcome.

Ding Y, Xu L, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Bergan RC.

J Biomol Tech. 2007 Dec;18(5):321-30.

44.

Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.

Kim YL, Jacobs DR Jr, Gross MD, Bergan RC, Gann PH, Liu K, Gapstur SM.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2781-3. No abstract available.

45.

A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.

Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ.

Cancer Invest. 2007 Dec;25(8):733-7. Epub 2007 Oct 18.

PMID:
17952740
46.

Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.

Craft CS, Xu L, Romero D, Vary CP, Bergan RC.

Mol Pharmacol. 2008 Jan;73(1):235-42. Epub 2007 Oct 19.

47.

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

Craft CS, Romero D, Vary CP, Bergan RC.

Oncogene. 2007 Nov 8;26(51):7240-50. Epub 2007 May 14.

48.

Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.

Ding Y, Xu L, Chen S, Jovanovic BD, Helenowski IB, Kelly DL, Catalona WJ, Yang XJ, Pins M, Ananthanarayanan V, Bergan RC.

Prostate Cancer Prostatic Dis. 2006;9(4):379-91. Epub 2006 Jun 20.

PMID:
16786039
50.

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

Eklund J, Kozloff M, Vlamakis J, Starr A, Mariott M, Gallot L, Jovanovic B, Schilder L, Robin E, Pins M, Bergan RC.

Cancer. 2006 Jun 1;106(11):2459-65.

Supplemental Content

Loading ...
Support Center